| Autor: |
Giovanna B, Carpentieri, Sandra E A B, Gonçalves, Mayra Z, Casagrande, Walid M, Mourad, Lara G C, Pinto, Maria Teresa, Zanella |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Obesity surgery. 32(8) |
| ISSN: |
1708-0428 |
| Popis: |
Since SGLT2 inhibitors may reduce postprandial hyperglycemia, this study aimed to evaluated whether empagliflozin might be useful in the treatment of postprandial hypoglycemia (PPH) postbariatric surgery (BS).Fourteen patients who underwent BS, nine without type 2 diabetes and five with diabetes before surgery and in remission after surgery, were included. Seven of them presented symptoms of PPH (hypoglycemic group; HG) and seven were asymptomatic (nonhypoglycemic group (NHG)). A meal tolerance test was performed before and after administration of a daily dose of empagliflozin (EMPA) 25 mg for 3 days. Plasma glucose and serum insulin levels were measured.In HG, compared with NHG, in the basal test, the area under the curve (AUC) of plasma glucose levels (AUCgly) was smaller (158.3 ± 25.3 vs 276.6 ± 79.2 mg h dLOur results suggest that empagliflozin increased glycemic levels in patients with PPH possibly through increases in hepatic glucose production. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink